Truncated Albumins as Novel Surrogate Biomarkers in Diabetes Therapy: Epiphenomena and Potential Clinical Applications
Metabolic Syndrome and Related Disorders · 2024
DOI: 10.1089/met.2024.0143 ↗Kurz gefasst
Fachartikel in der Zeitschrift Metabolic Syndrome and Related Disorders, 2024. Verfasst von Madhumati S Vaishnav und 5 weiteren Autor:innen. Beteiligte Einrichtung: Centre for Nano Science and Engineering, Indian Institute of Science, Bengaluru, India. Hauptthemen laut MEDLINE: Biomarkers, Diabetes Mellitus, Type 2, Serum Albumin, Human, Diabetes Mellitus, Type 1. Die Arbeit nennt 12 Literaturangaben.
Themen: Diabetes mellitus
Abstract (Originalsprache)
Aims/Hypothesis: Among various albumin posttranslational modifications (PTMs), N- and C-terminal truncations (HSA-DA and HSA-L) have also shown biomarker potential in disease states. We examined albumin truncation longitudinal trends and correlations during diabetes therapy toward possible future clinical applications.
Methods
In a preliminary longitudinal therapy investigation, mass spectrometry was employed to track PTMs of human serum albumin (HSA), including glycation (GA), cysteinylation (CA or HNA1; reversible), di/trioxidation (OA or HNA2; irreversible), and truncation (TA). These modifications were correlated with ongoing therapy in four distinct subject groups: type 1 diabetes (T1DM), type 2 diabetes (T2DM), prediabetes-obesity (PDOB), and healthy controls (NORM), observed over a follow-up period extending up to 280 days.
Results
Diabetes was associated with significant reduction ("deficiency") of measured albumin truncations (For HSA-DA: T2DM = 0.32 ± 0.3%, p = 2E-08; T1DM = 1.02 ± 0.4%, p = 3E-05; PDOB = 1.61 ± 0.2%, p = 0.004; compared to NORM = 2.08 ± 0.2%). Albumin truncation reduction was more striking in T2DM (HSA-DA: T2DM vs. T1DM: p = 0.004). Improvements in glycemic control and decrease of albumin glycation during diabetes therapy were associated with concomitant increase of albumin truncations toward the "healthy" normal ranges, and vice versa ("mirror image" trends). Accordingly, albumin truncation correlated inversely with albumin glycation (HSA-DA vs. GA: R = -0.53, p = 1E-09).
Conclusions
The "epiphenomenon" of albumin truncation (reflecting the severity of mean hyperglycemia and also insulin resistance) can possibly provide novel, sensitive, and complementary biomarkers (e.g., via simpler HSA-DA peptide fragment immunoassays) to monitor efficacy of diabetes therapy and also progression from "healthy" to prediabetes and type 2 diabetes, highlighting potential diagnostic and prognostic utility in clinical diabetes care.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Centre for Nano Science and Engineering, Indian Institute of Science, Bengaluru, India.
- Samatvam Endocrinology Diabetes Center, Jnana Sanjeevini Diabetes Hospital and Medical Center, Bengaluru, India.
- Mayo Clinic and Mayo University School of Medicine, Rochester, Minnesota, USA.
ORCID-Profile: Sathyanarayana Srikanta
Zitieren
APA
Vaishnav, M. S., Kumari, N., Srikanta, S., Simha, V., Krishnaswamy, P. R., & Bhat, N. (2024). Truncated Albumins as Novel Surrogate Biomarkers in Diabetes Therapy: Epiphenomena and Potential Clinical Applications. Metabolic Syndrome and Related Disorders. https://doi.org/10.1089/met.2024.0143
Vancouver
Vaishnav MS, Kumari N, Srikanta S, Simha V, Krishnaswamy PR, Bhat N. Truncated Albumins as Novel Surrogate Biomarkers in Diabetes Therapy: Epiphenomena and Potential Clinical Applications. Metabolic Syndrome and Related Disorders. 2024. doi:10.1089/met.2024.0143
BibTeX
@article{Vaishnav2024,
author = {Vaishnav, Madhumati S and Kumari, Namita and Srikanta, Sathyanarayana and Simha, Vinaya and Krishnaswamy, Patnam R and Bhat, Navakanta},
title = {Truncated Albumins as Novel Surrogate Biomarkers in Diabetes Therapy: Epiphenomena and Potential Clinical Applications},
journal = {Metabolic Syndrome and Related Disorders},
year = {2024},
doi = {10.1089/met.2024.0143}
}
EUVIMED